CervoMed公司宣布,计划在2026年下半年启动一项III期临床试验,旨在评估其候选药物Neflamapimod在路易体痴呆(DLB)患者中的疗效与安全性。这一举措标志着该药物研发进程中的重要一步,公司正积极推进其针对神经退行性疾病的治疗管线。
CervoMed公司宣布,计划在2026年下半年启动一项III期临床试验,旨在评估其候选药物Neflamapimod在路易体痴呆(DLB)患者中的疗效与安全性。这一举措标志着该药物研发进程中的重要一步,公司正积极推进其针对神经退行性疾病的治疗管线。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.